Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Stroke in Patients with AML vs General Population

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 19; Del Prete, et al

Publish date:: October 1, 2017

Patients with acute myeloid leukemia (AML) are more apt to experience a cerebrovascular accident (CVA) than those in the general inpatient population, according to a study involving nearly 7.3 million admissions. Moreover, their mortality rate is high. Participants were identified from the 2012 National Inpatient Sample. Investigators looked at age, gender, race, length of stay, in-hospital procedures, discharge diagnosis, disposition, and mortality rates. Among the results:

Nearly 11,000 patients had AML, and 65 of them also had a hemorrhagic or ischemic CVA.
The risk of stroke in this group was 50-times higher than it was in all admissions.
The mortality rate in patients with AML/CVA was 37%, vs 7% in all admitted patients with stroke.
After controlling for certain variables, acute renal failure with tubular necrosis, hypernatremia, urinary tract infection, and secondary thrombocytopenia were significant predictors of stroke.

Citation:

Del Prete C, Kim T, Lansigan F, Shatzel J, Friedman H. The epidemiology and clinical associations of stroke in patients with acute myeloid leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample. [Published online ahead of print September 19, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.008.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release